CHARLOTTESVILLE, Va., May 29, 2014 /PRNewswire/ -- HemoShear, the human disease biology company, has moved into a newly renovated state-of-the-art facility in Charlottesville to accommodate growth of partnerships with major pharmaceutical and biotechnology companies and expand its R&D capabilities. The facility provides 16,000 sq ft of combined laboratory and office space, more than doubling its current capacity. The new location also provides access to 12,000 sq ft of additional space for anticipated needs.
"In addition to accommodating our growing scientific and BioAnalytics staffs, the new laboratory space was designed specifically to optimize efficiency and quality of our R&D programs, and will enhance our ability to attract top talent to HemoShear," said Nicole Hastings, Ph.D., Vice President of Operations.
The additional laboratory space will enable the Company to further expand its first-in-class translational human tissue platforms that are essential to interrogate and interpret human disease biology with a high degree of precision. With these platforms, HemoShear will profile more diseases and further refine its investigative and predictive modeling, leading to novel discoveries and resolving previously unknown biological mechanisms that have frustrated the pharmaceutical industry.
"This move is an important milestone in HemoShear's progress," notes Jim Powers, CEO. "Our research and development partnerships in vascular and liver diseases with major pharmaceutical and biotechnology companies are growing in number and scope as the value of our platform becomes widely recognized. At the same time, we are accelerating the pace of development of new human biology systems, including tumors and rare diseases, which will lead to more partnerships requiring greater operational capacity and scientific expertise. HemoShear now has the capital base and the infrastructure to accommodate its growth over the next several years."
The Company's new address is:
501 Locust Ave, Suite 301
Charlottesville, VA 22902
P 434 872 0196
HemoShear, the human disease biology company, develops and applies first-in-class human disease systems to create safer and more effective therapies for patients. By integrating its proprietary technology, scientific expertise and advanced discovery and predictive analytics, HemoShear provides a unique lens to interpret biological mechanisms and human disease. The Company is changing the way drugs are discovered and developed, departing from traditional scientific methods and animal studies in favor of biological systems that more accurately represent human response. HemoShear works in partnership with pharmaceutical and biotechnology companies spanning discovery through clinical applications to uncover new targets, resolve previously unknown mechanisms, identify novel attributes of drugs and select candidates with superior efficacy and safety profiles. Through its innovative science, HemoShear's mission is to profoundly impact human health. THINK HUMAN.
For additional information, visit: www.hemoshear.com.
Feinstein Kean Healthcare
P 617 761 6766
M 508 851 0930